ANI Pharmaceuticals Releases Q2 2026 Financial Results
ANI Pharmaceuticals reported Q2 2026 results. Adjusted diluted EPS was $2.21, above the $2.09 estimate, and revenue rose to $266.0M from $211.4M a year earlier. Adjusted net income was $47.6M. Cortrophin Gel revenue was $117.1M, up 43.5%. Full-year adjusted EPS guidance is $9.19 to $9.69.
How this was made
The 30-second read
Why it matters
Q2 results and FY2026 adjusted EPS guidance are the primary actionable items, informing earnings revision risk and near-term positioning.
Market read
A straightforward earnings and guidance update with a beat and a specific full-year EPS range, typically driving analyst estimate changes and trading flows.
What to watch
No details are provided on cash flow, gross margin, R&D spend, competitive dynamics, or any risks to the pipeline that could affect how guidance is valued.
Background
ANI Pharmaceuticals is a biopharmaceutical company selling branded and generic products, with Cortrophin Gel highlighted as a key growth driver.
Ticker impact
ANI Pharmaceuticals reported Q2 2026 adjusted EPS of $2.21, beating $2.09, and set FY2026 adjusted EPS guidance of $9.19 to $9.69.
Likely positive reaction versus peers if guidance is viewed as credible and Cortrophin Gel growth sustains.
The article provides concrete EPS, revenue growth, and full-year guidance, which are direct drivers for earnings revisions and sentiment.
Market effects
Reinforces demand and execution strength in specialty biopharma, potentially supporting sentiment toward similar branded/generic hybrids.
No specific regional demand or regulatory change cited.
International revenue growth is mentioned, but no country-specific catalysts are provided.
Counterpoint
The beat may be partially offset by margin or product-mix concerns not discussed here, so the stock reaction could fade if investors scrutinize sustainability of Cortrophin Gel growth.
Key entities
- companyANI Pharmaceuticals, Inc.
Reported Q2 2026 adjusted EPS of $2.21, revenue of $266.0M, and FY2026 adjusted EPS guidance of $9.19 to $9.69.
- productCortrophin Gel
Flagship product with Q2 revenue of $117.1M, up 43.5% year over year.
